AI Article Synopsis
- Patients who undergo allogeneic hematopoietic cell transplantation (HCT) face various complications, both acute and long-term, including post-transplant diabetes mellitus (PTDM).
- PTDM is often overlooked but can significantly affect patients, similar to graft-versus-host disease (GVHD), both of which involve immune system issues.
- The review focuses on the role of the IL-33/ST2 cytokine axis in the development of acute GVHD and PTDM, suggesting it could be useful for predicting and treating immune and metabolic problems post-transplant.
Article Abstract
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft--host disease (GVHD), new-onset diabetes is characterized by immune dysregulation that can negatively impact transplant outcomes. This review will discuss the biology of IL-33/ST2 in acute GVHD and PTDM development, and how this cytokine axis could be leveraged for predicting and treating immuno-metabolic complications after transplant.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432328 | PMC |
| http://dx.doi.org/10.2991/chi.d.200506.002 | DOI Listing |
Publication Analysis
Top Keywords
immuno-metabolic complications
8
allogeneic hematopoietic
8
hematopoietic cell
8
predicting immuno-metabolic
4
complications allogeneic
4
cell transplant
4
transplant cytokine
4
cytokine interleukin-33
4
interleukin-33 il-33
4
il-33 receptor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!